rcc data at esmo 2020
Published 3 years ago • 97 plays • Length 1:43Download video MP4
Download video MP3
Similar videos
-
1:03
treating patients with rcc in 2020 and beyond
-
4:12
kidney cancer at esmo 2022: keynote-564 and prosper
-
5:08
update on biomarkers in urothelial cancer presented at esmo 2020
-
3:21
esmo 2020 highlights on pembrolizumab as 1st line therapy for auc: the keynote-361 study
-
5:35
dr. toni choueiri on clinically impactful new rcc data—practiceupdate's esmo 2016 coverage
-
9:57
how to select 1st line therapy for metastatic renal cell cancer?
-
7:25
#esmo21 expert video report on immunotherapy in gastro-oesophageal cancer
-
3:18
immune checkpoint inhibitors and combination strategies for patients with gastric cancer
-
19:24
adaptimmune reports updated surpass data at esmo 2021
-
5:07
esmo 2020 expert video report on 1st line ici for gastro oesophageal cancer
-
3:04
esmo 2020 highlights on durability of clinical benefit and biomarkers with amg510 in nsclc
-
10:09
esmo 2020 expert video report on long term ici outcomes in lung cancer
-
8:17
practice changers in rcc from esmo 2017
-
7:36
esmo 2020 expert video report on atezolizumab in upfront treatment of tnbc
-
2:57
esmo 2020 highlights on lenvatinib plus pembrolizumab in advanced solid tumours: leap-005
-
1:22
uro-onc data at esmo 2018: what to look out for
-
8:51
esmo 2020 expert video report on precision medicine in prostate cancer
-
2:05
esmo 2020 highlights on nivolumab cabozantinib as 1st line therapy for arcc: the checkmate 9er study
-
1:02
key rcc data: javelin renal 101 & checkmate 214
-
1:30
rcc treatment: future remarks
-
5:32
esmo 2020 expert video report on cdk4 6i in the adjuvant treatment of breast cancer